Jul 20, 2017 Last Updated 12:22 PM, Jul 17, 2017

Methotrexate has no steroid-sparing effect in patients with generalized myasthenia gravis

Published in News
Read 937 times
Rate this item
(0 votes)

Myasthenia gravis (MG) is a chronic autoimmune disease characterized by fluctuating muscle weakness, which, in the majority of patients, is treated with corticosteroids. In a recently published clinical trial, 50 patients with generalized MG were randomly assigned to prednisone + methotrexate or prednisone + placebo. The amount of prednisone that…

Nature Reviews Neurology; June 2016

Full Text

 

Last modified on Saturday, 02 July 2016 09:45
Login to post comments

Registered area

Thanks to the support of
merck serono biogen sanofi

JNIInternational Brain Research Organization
Bringing Neuroscience to the World
JNIJournal of Neuroimmunology
Studies on all branches of neurosciences covering both research and clinical problems of neuroscientific interest.

This website or its third party tools use cookies, which are necessary to its functioning and required to achieve the purposes illustrated in the cookie policy. If you want to know more or withdraw your consent to all or some of the cookies, please refer to the cookie policy. By closing this banner, scrolling this page, clicking a link or continuing to browse otherwise, you agree to the use of cookies. To find out more about the cookies we use and how to delete them, see our Cookie Policy